Correction of Termination of Single Sales/Supply Contract and Continuous Disclosure Reservation


  • Disclosure of contract termination and disclosure reservation correction (correction date: 2026-04-30)
  • Out of original contract amount of 488,800,000 KRW, actual performance amount is only 143,000,000 KRW (29.3%)
  • Continuous disclosure reservation due to counterparty's request (protection of trade secrets)
  • Contract end date: 2026-04-30 (expiration and termination)
  • Only summary information provided per KOSDAQ disclosure regulations

KOSDAQ Filing Information


  • Filing: [Correction of Description] Conclusion of Single Sale and Supply Contract
  • Company: Prestige Biologics (334970)
  • Submission: Prestige Biologics Co., Ltd.
  • Receipt: 04-30-2026
  • Under KRX KOSDAQ Market Division